Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-na ïve, HER2-positive advanced gastric cancer
ConclusionsTrastuzumab with SOX had promising activity with well-tolerated toxicities for patients with HER2-positive AGC.Clinical trial registrationUMIN000017602.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Japan Health | Neurology | Study | Toxicology